- ►duanesolution.com PG THEODOSSIADIS, NN MARKOMICHELAKIS … - Retina, 2007 - journals.lww.com The anti-tumor necrosis factor (TNF) monoclonal antibody infliximab and the
soluble TNF receptor etanercept inhibit the pleiotropic actions of TNF and are
widely used for the treatment of rheumatoid arthritis (RA), juvenile ... Cited by 33 - Related articles - BL Direct - All 6 versions
- Free from Publisher C Hernandez, A Fonollosa, M Garcia-Ramirez, … - Diabetes care, 2006 - Am Diabetes Assoc OBJECTIVE—Erythropoietin has been recently found to be increased in the
vitreous fluid from ischemic retinal diseases such as proliferative diabetic
retinopathy (PDR). The aims of the present study were 1) to measure ... Cited by 25 - Related articles - BL Direct - All 6 versions
JM Gonzalez-Clemente, D Mauricio, C Richart … - Clinical Endocrinology, 2005 - pt.wkhealth.com Results: Thirty-six subjects had DN and 84 did not. Subjects with DN received
higher insulin doses (57·6 ± 16·7 vs. 49·2 ± 15·0 IU/day; P = 0·008) and
had higher WHR (0·85 ± 0·07 vs. 0·81 ± 0·10; P = 0·007) and HbA1c ... Cited by 19 - Related articles - BL Direct - All 4 versions
- Free from Publisher R Simó, E Carrasco, A Fonollosa, J García- … - Diabetes care, 2007 - Am Diabetes Assoc Although diabetic macular edema (DME) is the main cause of visual loss in type 2
diabetic patients (1), its pathogenic mechanisms have been much less studied
than proliferative diabetic retinopathy (PDR). The production of both ... Cited by 9 - Related articles - BL Direct - All 5 versions
AP Adamis, AJ Berman - Seminars in Immunopathology, 2008 - Springer Abstract There is an accumulating body of evidence that immunological mechanisms
play a prominent role in the pathogenesis of diabetic retinopathy (DR), which is
charac- terized by many features typical of inflammation. The upregulation ... Cited by 7 - Related articles - BL Direct - All 3 versions
MK Tsilimbaris, TD Panagiotoglou, SK Charisis … - Seminars in Ophthalmology, 2007 - informahealthcare.com The aim of this pilot study was to investigate the effect of intravitreal
administration of etanercept in refractory diabetic macular edema. Seven
patients diagnosed with diabetic macular edema, refractory to previous ... Cited by 5 - Related articles - BL Direct - All 5 versions
AM Joussen, AP Adamis - cytokines - Springer Inthe past few decades, our knowledge of the mecha- nisms underlying retinal
vasoproliferation has increased greatly (see Chapters 2, 3.1, 3.2 and 3.3).
While vasoproliferation was once considered to be mainly a consequence of ... Cited by 2 - Related articles
PG Theodossiadis, VS Liarakos, PP Sfikakis, … - Graefe's Archive for Clinical and Experimental …, 2009 - Springer Page 1. MEDICAL OPHTHALMOLOGY Intravitreal administration of the anti-TNF
monoclonal antibody Infliximab in the rabbit Panagiotis ... Cited by 2 - Related articles - All 2 versions
R Sharma, CL Sharma - Indian J Crit Care Med, 2007 - Medknow Advances in the DNA hybrid technology led to the development of various
biologicals that specifically target TNF-a. There are currently three anti-
TNF-a drugs available- etanercept, infliximab and adalimumab. Etanercept is ... Cited by 1 - Related articles - All 5 versions
A Reiff, SM Hampton, R Payne - US Patent App. 11/280,377, 2005 - Google Patents US 20060110429A1 (19) United States (12) Patent Application Publication GO) Pub.
NO.: US 2006/0110429 Al Reiff et al. (43) Pub. Date: May 25,2006 (54) IMPLANT
FOR INTRAOCULAR DRUG DELIVERY (75) Inventors: Andreas Reiff, San Marino, CA ... Related articles - All 6 versions
